Medicare Enrolled
Dr. Devesh Pandya, M.D.
Hematology & Oncology · Houston, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Pandya from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Pandya?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Pandya
Dr. Devesh Pandya is a hematology & oncology specialist in Houston, TX, with 18 years of NPI registration. Based on federal Medicare data, Dr. Pandya performed 38,784 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Pandya received a total of $1,698,245 from 52 pharmaceutical and/or device companies across 1332 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Pandya is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years of NPI registration
▲ Top 25% volume in TX
$1,698,245 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗38,784
Medicare services
Top 25% in TX for hematology & oncology
Not available
Unique patients (not deduplicated)
$5
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
25,500 | $0 | $2 |
| Contrast dye for imaging (iodine-based) A contrast agent containing 300-399 mg/ml of iodine used to enhance imaging studies. It is administered per milliliter to improve the visibility of internal structures. |
8,350 | $0 | $0 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,000 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 930 | $1 | $4 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
908 | $8 | $24 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
371 | $90 | $393 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
181 | $132 | $557 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
151 | $22 | $90 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
151 | $7 | $36 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
135 | $99 | $414 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
122 | $8 | $10 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
119 | $11 | $51 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
118 | $12 | $53 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
88 | $46 | $204 |
| Office visit for established patient An office visit for an existing patient that may not require the healthcare professional to be present. |
82 | $16 | $72 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
81 | $59 | $277 |
| Basic blood chemical test (calcium, ionized) A blood test that measures basic chemical levels, specifically including calcium and ionized calcium. |
69 | $13 | $42 |
| CT scan of chest with contrast A computed tomography scan of the chest using a contrast dye to enhance the visibility of internal structures. |
68 | $58 | $567 |
| Blood creatinine level test A blood test that measures the amount of creatinine, a waste product from muscle wear and tear, to help assess kidney function. |
64 | $5 | $16 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
63 | $19 | $89 |
| Nuclear medicine scan from skull base to mid-thigh with CT A nuclear medicine imaging study covering the area from the base of the skull to the middle of the thighs, performed alongside a CT scan. |
56 | $1,191 | $5,354 |
| New patient office visit, complex (60-74 min) | 53 | $169 | $688 |
| CT scan of abdomen and pelvis with contrast A CT scan that uses dye to create detailed images of the abdomen and pelvis. This imaging test helps doctors examine internal organs and structures in these areas. |
47 | $188 | $1,027 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 47 | $101 | $506 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
30 | $120 | $519 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
66.7% high complexity
28.1% medium
5.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$1,698,245
Total received (2018-2024)
Avg $242,606/year across 7 years
Top 0% in TX for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
52
Companies
1,332
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$429,518
2023
$330,814
2022
$253,079
2021
$131,336
2020
$109,980
2019
$192,502
2018
$251,015
Payments by company (2024)
GlaxoSmithKline, LLC.
$87,938
Gilead Sciences, Inc.
$85,142
JAZZ PHARMACEUTICALS INC.
$68,687
Myriad Genetic Laboratories, Inc.
$45,781
E.R. Squibb & Sons, L.L.C.
$44,439
EMD Serono, Inc.
$42,542
AstraZeneca Pharmaceuticals LP
$24,598
Janssen Biotech, Inc.
$15,250
PFIZER INC.
$7,934
Janssen Pharmaceuticals, Inc
$3,796
Ipsen Biopharmaceuticals, Inc
$1,741
Astellas Pharma US Inc
$1,037
SpringWorks Therapeutics, Inc.
$146
Novartis Pharmaceuticals Corporation
$88
GENZYME CORPORATION
$83
BeiGene USA, Inc.
$74
Sirtex Medical Inc
$59
Daiichi Sankyo Inc.
$54
Kite Pharma, Inc.
$35
TAIHO ONCOLOGY, INC.
$25
Genentech USA, Inc.
$22
Stemline Therapeutics Inc.
$16
Celgene Corporation
$16
PUMA BIOTECHNOLOGY, INC.
$16
Top 3 companies account for 56.3% of 2024 payments
All-time payments by company (2018-2024) ›
E.R. Squibb & Sons, L.L.C.
$584,900
GlaxoSmithKline, LLC.
$258,426
Gilead Sciences, Inc.
$153,294
Myriad Genetic Laboratories, Inc.
$117,310
Boehringer Ingelheim Pharmaceuticals, Inc.
$110,722
EMD Serono, Inc.
$74,925
JAZZ PHARMACEUTICALS INC.
$68,687
AstraZeneca Pharmaceuticals LP
$61,638
PFIZER INC.
$52,058
Amgen Inc.
$45,769
Karyopharm Therapeutics Inc.
$37,794
Janssen Pharmaceuticals, Inc
$30,999
Janssen Biotech, Inc.
$25,793
GENZYME CORPORATION
$18,419
Foundation Medicine, Inc.
$16,057
Helsinn Therapeutics (U.S.), Inc.
$9,008
Celgene Corporation
$8,262
Kite Pharma, Inc.
$4,945
Acceleron Pharma, Inc.
$4,495
Spectrum Pharmaceuticals Inc.
$2,663
Fresenius Kabi USA, LLC
$2,550
Astellas Pharma US Inc
$1,967
Ipsen Biopharmaceuticals, Inc
$1,741
Seattle Genetics, Inc.
$1,571
R-Pharm US LLC
$1,323
Janssen Scientific Affairs, LLC
$818
BeiGene USA, Inc.
$321
Novartis Pharmaceuticals Corporation
$280
Genentech USA, Inc.
$276
PUMA BIOTECHNOLOGY, INC.
$149
SpringWorks Therapeutics, Inc.
$146
Regeneron Healthcare Solutions, Inc.
$124
Stemline Therapeutics Inc.
$123
Lilly USA, LLC
$114
Daiichi Sankyo Inc.
$77
Bayer Healthcare Pharmaceuticals Inc.
$74
Sirtex Medical Inc
$71
Seagen Inc.
$43
Takeda Pharmaceuticals U.S.A., Inc.
$38
ARRAY BIOPHARMA INC
$37
Puma Biotechnology, Inc.
$25
TAIHO ONCOLOGY, INC.
$25
Exelixis Inc.
$24
Myriad Women's Health, Inc.
$23
Incyte Corporation
$20
PharmaEssentia USA Corporation
$19
EISAI INC.
$19
Pharming Healthcare, Inc.
$19
Verity Pharmaceuticals Inc.
$19
Taiho Oncology, Inc.
$18
Secura Bio, Inc.
$15
EUSA Pharma (US) LLC
$15
Top 3 companies account for 58.7% of all-time payments
Associated products mentioned in payments ›
ABECMA · ADCETRIS · AKYNZEO · ALOXI · AUGTYRO · BALVERSA · BAVENCIO · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · CABOMETYX · CHANTIX · CYRAMZA · DARZALEX · ELIQUIS · EMPLICITI · ENDOPREDICT · ENJAYMO · ERLEADA · EndoPredict · Enhertu · FOUNDATIONONE · FOUNDATIONONE LIQUID · Fabhalta · Farydak · Folotyn · GENESIGHT · GILOTRIF · IBRANCE · IMFINZI · IMJUDO · Ixempra · JEMPERLI · JEVTANA · KISQALI · Kyprolis · LIBTAYO · LONSURF · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · MYCHOICE CDX · MYRISK · NERLYNX · NINLARO · Nplate · Nubeqa · OGSIVEO · OJJAARA · ONUREG · OPDIVO · OPDUALAG · OXBRYTA · Onivyde · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PRECISETUMOR · PROMACTA · Padcev · Pomalyst · PreciseTumor · REBLOZYL · RUCONEST · RYBREVANT · Reblozyl · SCEMBLIX · SIR-Spheres Microspheres · SUTENT · Sylvant · TECENTRIQ · Tazverik · Tecartus · Tecentriq · Trelstar · Trodelvy · VENCLEXTA · VERZENIO · Venclexta · XALKORI · XARELTO · XPOVIO · XTANDI · XYNTHA · Xospata · Yescarta · ZEJULA · ZEPZELCA · ZYKADIA · Zevalin · myChoice CDx · myRisk
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Hematology & oncology specialists in nearby ZIP areas
202
County median income
$73,104
Nearest hospital to ZIP centroid (approximate)
MEMORIAL HERMANN - TEXAS MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Pandya is a mixed practice specialist, with above-average Medicare volume (top 25% in TX), with 18 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Pandya experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Pandya performed 25,500 iron infusion (feraheme) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Pandya receive payments from pharmaceutical companies?
Yes. Dr. Pandya received a total of $1,698,245 from 52 companies across 1,332 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Pandya's costs compare to other hematology & oncology specialists in Houston?
Dr. Pandya's average Medicare payment per service is $5. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Pandya) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Houston
Browse hematology & oncology specialists in Houston ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in TX
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in TX
Which TX hematology & oncology specialists receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
Gilead Sciences, Inc. Payments to Doctors
See all physicians who received payments from Gilead Sciences, Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology